ACT-451840   Click here for help

GtoPdb Ligand ID: 10022

Synonyms: ACT451840 | Actelion-451840
Antimalarial Ligand
Compound class: Synthetic organic
Comment: ACT-451840 is an investigational antimalarial drug, selected from a new class of compounds identified from a phenotypic screen [2,4]. Chemically it is a piperazine-containing compound.

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 0
Rotatable bonds 15
Topological polar surface area 91.2
Molecular weight 750.43
XLogP 7.49
No. Lipinski's rules broken 2
Click here for help
Canonical SMILES N#Cc1ccc(cc1)CN1CCN(CC1)C(=O)[C@@H](N(C(=O)/C=C/c1ccc(cc1)C(C)(C)C)Cc1ccc(cc1)N1CCN(CC1)C(=O)C)Cc1ccccc1
Isomeric SMILES N#Cc1ccc(cc1)CN1CCN(CC1)C(=O)[C@@H](N(C(=O)/C=C/c1ccc(cc1)C(C)(C)C)Cc1ccc(cc1)N1CCN(CC1)C(=O)C)Cc1ccccc1
InChI InChI=1S/C47H54N6O3/c1-36(54)50-28-30-51(31-29-50)43-21-16-41(17-22-43)35-53(45(55)23-18-37-14-19-42(20-15-37)47(2,3)4)44(32-38-8-6-5-7-9-38)46(56)52-26-24-49(25-27-52)34-40-12-10-39(33-48)11-13-40/h5-23,44H,24-32,34-35H2,1-4H3/b23-18+/t44-/m0/s1
1. Aissaoui H., Boss C., Corminboeuf O., Heidmann B., Siegrist R. (2011)
Piperazines as antimalarial agents.
Patent number: WO2011083413A1. Assignee: Actelion Pharmaceuticals Ltd.. Priority date: 05/01/2010. Publication date: 14/07/2011.
2. Boss C, Aissaoui H, Amaral N, Bauer A, Bazire S, Binkert C, Brun R, Bürki C, Ciana CL, Corminboeuf O et al.. (2016)
Discovery and Characterization of ACT-451840: an Antimalarial Drug with a Novel Mechanism of Action.
ChemMedChem, 11 (18): 1995-2014. [PMID:27471138]
3. Bruderer S, Hurst N, de Kanter R, Miraval T, Pfeifer T, Donazzolo Y, Dingemanse J. (2015)
First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity.
Antimicrob Agents Chemother, 59 (2): 935-42. [PMID:25421475]
4. Brunner R, Aissaoui H, Boss C, Bozdech Z, Brun R, Corminboeuf O, Delahaye S, Fischli C, Heidmann B, Kaiser M et al.. (2012)
Identification of a new chemical class of antimalarials.
J Infect Dis, 206 (5): 735-43. [PMID:22732921]
5. Brunner R, Ng CL, Aissaoui H, Akabas MH, Boss C, Brun R, Callaghan PS, Corminboeuf O, Fidock DA, Frame IJ et al.. (2013)
UV-triggered affinity capture identifies interactions between the Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) and antimalarial agents in live parasitized cells.
J Biol Chem, 288 (31): 22576-83. [PMID:23754276]
6. Krause A, Dingemanse J, Mathis A, Marquart L, Möhrle JJ, McCarthy JS. (2016)
Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects.
Br J Clin Pharmacol, 82 (2): 412-21. [PMID:27062080]
7. Le Bihan A, de Kanter R, Angulo-Barturen I, Binkert C, Boss C, Brun R, Brunner R, Buchmann S, Burrows J, Dechering KJ et al.. (2016)
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.
PLoS Med, 13 (10): e1002138. [PMID:27701420]
8. Ng CL, Siciliano G, Lee MC, de Almeida MJ, Corey VC, Bopp SE, Bertuccini L, Wittlin S, Kasdin RG, Le Bihan A et al.. (2016)
CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs.
Mol Microbiol, 101 (3): 381-93. [PMID:27073104]